Download MendeleyAtropisomer Control in Macrocyclic Factor VIIa Inhibitors.
Glunz, P.W., Mueller, L., Cheney, D.L., Ladziata, V., Zou, Y., Wurtz, N.R., Wei, A., Wong, P.C., Wexler, R.R., Priestley, E.S.(2016) J Med Chem 59: 4007-4018
- PubMed: 27015008 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.6b00244
- Primary Citation Related Structures:
5I46 - PubMed Abstract:
Incorporation of a methyl group onto a macrocyclic FVIIa inhibitor improves potency 10-fold but is accompanied by atropisomerism due to restricted bond rotation in the macrocyclic structure, as demonstrated by NMR studies. We designed a conformational constraint favoring the desired atropisomer in which this methyl group interacts with the S2 pocket of FVIIa. A macrocyclic inhibitor incorporating this constraint was prepared and demonstrated by NMR to reside predominantly in the desired conformation. This modification improved potency 180-fold relative to the unsubstituted, racemic macrocycle and improved selectivity. An X-ray crystal structure of a closely related analogue in the FVIIa active site was obtained and matches the NMR and modeled conformations, confirming that this conformational constraint does indeed direct the methyl group into the S2 pocket as designed. The resulting rationally designed, conformationally stable template enables further optimization of these macrocyclic inhibitors.
- Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States.
Organizational Affiliation:
